Fluralaner (Synonyms: A-1443, AH 252723) |
| Catalog No.GC18295 |
Le Fluralaner (DCI) est un Fluralaner insecticide et acaricide systémique par blocage puissant des canaux de chlorure activés par le GABA et le L-glutamate.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 864731-61-3
Sample solution is provided at 25 µL, 10mM.
Fluralaner (INN) is a systemic insecticide and acaricide Fluralaner through potent blockage of GABA and L-glutamate gated chloride channels.
Fluralaner potently inhibits flea reproduction capacity in vitro. Oviposition ceases completely at concentrations as low as 25.0 ng/mL. While no ovicidal effect is observed, fluralaner exerts a larvicidal effect at exceptionally low concentrations (6.25 ng/mL)[1].
In the simulated flea-infested home environment, flea-control efficacy on fluralaner-treated dogs is >99% at every time point measured for 12 weeks. No adverse events are observed in fluralaner-treated dogs. Fluralaner completely controls egg laying, larval development and flea reproduction even at sub-insecticidal concentrations. Oral treatment of dogs with fluralaner is highly effective for eliminating fleas in a simulated flea-infested home environment[1]. After single oral administration of Bravecto chewable tablets, mite numbers in skin scrapings are reduced by 99.8% on Day 28 and by 100% on Days 56 and 84. A marked decrease is observed in the occurrence of erythematous patches, crusts, casts and scales in the dogs treated with Bravectco[2].
References:
[1]. Williams H, et al. Fluralaner, a novel isoxazoline, prevents flea (Ctenocephalides felis) reproduction in vitro and in asimulated home environment. Parasit Vectors. 2014 Jun 19;7:275.
[2]. Walther FM, et al. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration. Parasit Vectors. 2014 Mar 6;7:86.
|
Animal experiment: |
Dogs: Thirty-two (16 male and 16 female) healthy 8-week old Beagle dogs weighing 2.0 - 3.6 kg at first administration are included in the study. Fluralaner is administered on three occasions at 8-week intervals at doses of up to 56, 168, and 280 mg fluralaner/kg body weight, equivalent to 1, 3, and 5 times the highest recommended treatment dose of fluralaner; sham dosed dogs served as controls[2]. |
|
References: [1]. Williams H, et al. Fluralaner, a novel isoxazoline, prevents flea (Ctenocephalides felis) reproduction in vitro and in asimulated home environment. Parasit Vectors. 2014 Jun 19;7:275. |
|
| Cas No. | 864731-61-3 | SDF | |
| Synonymes | A-1443, AH 252723 | ||
| Chemical Name | 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-benzamide | ||
| Canonical SMILES | CC1=CC(C2=NOC(C3=CC(Cl)=CC(Cl)=C3)(C(F)(F)F)C2)=CC=C1C(NCC(NCC(F)(F)F)=O)=O | ||
| Formula | C22H17Cl2F6N3O3 | M.Wt | 556.3 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7976 mL | 8.988 mL | 17.9759 mL |
| 5 mM | 359.5 μL | 1.7976 mL | 3.5952 mL |
| 10 mM | 179.8 μL | 898.8 μL | 1.7976 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *















